Andrade JG, Verma A, Mitchell LB, et al; CCS Atrial Fibrillation Guidelines Committee. 2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2018 Nov;34(11):1371-1392. doi: 10.1016/j.cjca.2018.08.026. PubMed PMID: 30404743.
January CT, Wann LS, Alpert JS, et al; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014 Dec 2;130(23):e199-267. doi: 10.1161/CIR.0000000000000041. Epub 2014 Mar 28. Erratum in: Circulation. 2014 Dec 2;130(23):e272-4. PubMed PMID: 24682347; PubMed Central PMCID: PMC4676081.
Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013 Dec;10(12):1932-63. doi: 10.1016/j.hrthm.2013.05.014. Epub 2013 Aug 30. Review. PubMed PMID: 24011539.
Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013 Aug;34(29):2281-329. doi: 10.1093/eurheartj/eht150. Epub 2013 Jun 24. PubMed PMID: 23801822.
American College of Cardiology Foundation; American Heart Association; European Society of Cardiology; Heart Rhythm Society, Wann LS, Curtis AB, Ellenbogen KA, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2013 May 7;127(18):1916-26. doi: 10.1161/CIR.0b013e318290826d. Epub 2013 Apr 1. PubMed PMID: 23545139.
Camm AJ, Lip GY, De Caterina R, et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012 Nov;33(21):2719-47. doi: 10.1093/eurheartj/ehs253. Epub 2012 Aug 24. Erratum in: Eur Heart J. 2013 Mar;34(10):790. Eur Heart J. 2013 Sep;34(36):2850-1. PubMed PMID: 22922413.
Tracy CM, Epstein AE, Darbar D, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Heart Rhythm Society. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. [corrected]. Circulation. 2012 Oct 2;126(14):1784-800. doi: 10.1161/CIR.0b013e3182618569. Epub 2012 Sep 10. Erratum in: Circulation. 2013 Jan 22;127(3):e357-9. Heart Rhythm Society [added]. PubMed PMID: 22965336.
Pediatric and Congenital Electrophysiology Society (PACES); Heart Rhythm Society (HRS); American College of Cardiology Foundation (ACCF); American Heart Association (AHA); American Academy of Pediatrics (AAP); Canadian Heart Rhythm Society (CHRS), Cohen MI, Triedman JK, Cannon BC, et al. PACES/HRS expert consensus statement on the management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular preexcitation) electrocardiographic pattern: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), the American Academy of Pediatrics (AAP), and the Canadian Heart Rhythm Society (CHRS). Heart Rhythm. 2012 Jun;9(6):1006-24. doi: 10.1016/j.hrthm.2012.03.050. Epub 2012 May 10. PubMed PMID: 22579340.
European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010 Oct;31(19):2369-429. doi: 10.1093/eurheartj/ehq278. Epub 2010 Aug 29. Erratum in: Eur Heart J. 2011 May;32(9):1172. PubMed PMID: 20802247.
Definition, Etiology, PathogenesisTop
Congenital long-QT syndrome (LQTS) refers to genetic abnormalities of ion channels (channelopathies) characterized by a long QT interval with an increased risk of polymorphic ventricular tachycardia (VT) (torsades de pointes) and sudden cardiac death (SCD). Overall, 13 types of LQTS caused by >500 mutations have been identified. The most common clinical types are types 1, 2, and 3 (LQT1, LQT2, LQT3).
Clinical Features and Natural HistoryTop
Most patients are asymptomatic. Syncope can occur, commonly caused by ventricular tachyarrhythmia or ventricular fibrillation (VF). Episodes may be triggered by emotions, exercise, or noise. Family history includes syncope or SCD, particularly at a young age. The condition is associated with an elevated risk of SCD, especially in patients with a history of syncope, QTc >500 milliseconds, documented polymorphic VT, prior cardiac arrest, and when combined with syndactyly or deafness syndromes.
Diagnosis is based on clinical symptoms, history, genetic studies, and electrocardiography (ECG) results: The normal upper limit for QTc is 470 milliseconds in adult men and 480 milliseconds in adult women, with a significant overlap between the normal spectrum and genetically affected individuals with no or only mild QT prolongation. Concealed long QT may be unmasked by either an exercise test or epinephrine challenge. The occurrence of torsades de pointes depends on the degree of QT prolongation and most of the times is triggered by a short—long—short sequence (ventricular premature beat [VPB]—pause after the VPB—another VPB and tachycardia).
Genetic studies play an important role in the diagnosis of LQTS as well as in prognosis assessment and therapeutic decision-making.
Acquired LQTS may present with syncope, SCD, or polymorphic VT (torsades de pointes). Causes include electrolyte disturbances (hypokalemia, hypomagnesemia, hypocalcemia) or drugs such as antiarrhythmic agents (amiodarone, sotalol), antihistamines (hydroxyzine, loratadine, terfenadine), antimicrobial agents (erythromycin, clarithromycin, moxifloxacin, trimethoprim), antimalarial drugs (chloroquine), or psychiatric drugs; a complete list of agents can be found at crediblemeds.org. Symptoms of acquired LQTS are very similar to those of congenital LQTS, with ECG also showing prolonged QT intervals. A thorough history including all drugs taken by the patient and measurements of serum potassium, magnesium, and calcium are crucial for diagnosis.
Classification of antiarrhythmic drugs: Table 3.4-1.
Antiarrhythmic agents: Table 3.4-2.
1. Avoid drugs causing QT prolongation.
2. Correct electrolyte disturbances.
3. Eliminate triggers (strenuous activity in patients with LQT1).
4. Beta-blocker treatment at the maximum tolerated doses is indicated, particularly in patients with LQT1 and LQT2. The preferred agents are nadolol and propranolol. In patients with LQT3, flecainide may be effective.
5. Placement of an implantable cardioverter-defibrillator (ICD) is indicated after seeking expert advice for secondary prevention of SCD in patients with a history of cardiac arrest as well as malignant syncope, VT, or both despite beta–blocker therapy. Prophylactic implantation of an ICD may be advisable in patients at high risk of SCD, (eg, with extremely long QT, congenital deafness, double mutations, or mutations associated with a particularly high risk of SCD). In patients in whom beta-blockers are contraindicated, poorly tolerated, or ineffective, surgical removal of the left stellate (sympathetic) ganglion is an option.
6. Pacemaker implantation may be useful in patients with congenital or acquired LQTS where ventricular arrhythmias are related to pauses or bradyarrhythmia.